---
title: "600436.SH (600436.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600436.SH/news.md"
symbol: "600436.SH"
name: "600436.SH"
parent: "https://longbridge.com/en/quote/600436.SH.md"
datetime: "2026-05-21T02:15:05.441Z"
locales:
  - [en](https://longbridge.com/en/quote/600436.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600436.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600436.SH/news.md)
---

# 600436.SH (600436.SH) — Related News

### [ZZPZH "leveraged increase" mystery: 90% state-owned capital loan support, can it withstand the disappearance of a market value of 200 billion yuan ｜ Traditional Chinese Medicine Rust Belt](https://longbridge.com/en/news/286380326.md)
*2026-05-14T07:28:09.000Z*
> ZZPZH's controlling shareholder, Jiulongjiang Group, increased its stake by 500 million yuan, with funds primarily sourc

### [ZZPZH target price increased by over 50%, Zhou Dasheng and others' ratings downgraded | Brokerage Rating Observation](https://longbridge.com/en/news/286020421.md)
*2026-05-12T01:34:12.000Z*
> On May 11th, brokerages made 55 adjustments to the target prices of listed companies, with the target price of ZZPZH inc

### [ZZPZH's core products are under pressure, and profits have significantly declined. The future of the "Pharmaceutical Moutai" transformation remains uncertain](https://longbridge.com/en/news/285922208.md)
*2026-05-11T10:09:07.000Z*
> ZZPZH experienced its first decline in both revenue and net profit in 2025, with decreases of 16.56% and 27.49%, respect

### [ZZPZH is trapped in the "dependency" on big single products](https://longbridge.com/en/news/285772632.md)
*2026-05-08T20:21:14.000Z*
> ZZPZH stated at the 2025 and Q1 2026 earnings conference that in the face of market and economic pressures, the company 

### [A large number of OTC price reductions, chain pharmacies are having a tough time](https://longbridge.com/en/news/285051531.md)
*2026-05-04T09:27:29.000Z*
> On April 30th, the fourth batch of national Chinese patent medicine alliance procurement opened bidding in Wuhan, for th

### ["Old Deng's stock" is a complete failure](https://longbridge.com/en/news/284963289.md)
*2026-05-02T10:01:32.000Z*
> ZZPZH released its worst annual report in history on April 29, with revenue of 9.001 billion yuan in 2025, a year-on-yea

### ["Pharmaceutical King" ZZPZH sees double decline in profits, cash flow drops over 90%](https://longbridge.com/en/news/284862394.md)
*2026-05-01T02:29:42.000Z*
> ZZPZH released its 2025 annual report and 2026 Q1 report, showing a decline in both revenue and net profit, with the dec

### [Healthcare Industry Daily (04.30): Breakthroughs in Pharmaceutical Innovation](https://longbridge.com/en/news/284822551.md)
*2026-04-30T19:12:18.000Z*
> BeOne Medicines' anti-PD-1 monoclonal antibody combination therapy has received FDA priority review for the treatment of

### [ZZPZH's controlling shareholder has cumulatively increased their stake by 0.53% in the company](https://longbridge.com/en/news/284773233.md)
*2026-04-30T12:42:03.000Z*
> The controlling shareholder of ZZPZH, Jiulongjiang Group, increased its holdings by 3.1713 million shares through centra